AI 聊天
Loading data for GEHC — first visit, this takes a few seconds.

GE HealthCare Technologies Inc.

GEHC · NasdaqGS · USD

64.07 -0.18 (-0.28%)

收盤價: Sep 15, 2026, 3:59 PM

64.25 +0.28%

盤後: 7:58 PM

市值
$28.94B
成交量
4.17M
下次財報日期
Oct 28, 2026

GE HealthCare Technologies Inc.(GEHC)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →
營收 (ttm)
$21.27B

正在載入...

最新財報

已通報較預期YoY 變更
營收$5.29Bn/a+5.75%
EPS$1.13+$0.09+6.60%

下次財報

開盤前。

估計 · 升級 →

查看財報詳情 →

指標

買價
59.15
市值
28.9B
淨利(ttm)
1.98B
0.82
4.34
14.76
11.84
P/B (ttm)
2.64
P/S (ttm)
1.37
財報日期
Oct 28, 2026
賣價
69.3
成交量
4,174,332
20 日平均成交量
4,386,143
開盤價
64.20
前收盤價
64.25
當日區間
63.61 - 64.64
52 週範圍
58.75 - 89.77
股利
$0.14 (0.22%)
除息日
Jul 24, 2026

關於 GE HealthCare Technologies Inc.

查看公司資料 →
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois. Medical Devices · Healthcare

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

類股 Healthcare
IPO 日期 Dec 15, 2022
員工 54,000
證券交易所 NasdaqGS
股票代號 GEHC